Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report

Agarwal, 2017, Kawasaki disease: etiopathogenesis and novel treatment strategies, Expert Rev Clin Immunol., 13, 247, 10.1080/1744666X.2017.1232165

Riphagen, 2020, Hyperinflammatory shock in children during COVID-19 pandemic, Lancet., 395, 1607, 10.1016/S0140-6736(20)31094-1

Verdoni, 2020, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study, Lancet., 395, 1771, 10.1016/S0140-6736(20)31103-X

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19).

Force, 2012, Acute respiratory distress syndrome: the Berlin Definition, JAMA., 307, 2526, 10.1001/jama.2012.5669

Belot, 2020, SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020, Euro Surveill., 25, 10.2807/1560-7917.ES.2020.25.22.2001010

Grimaud, 2020, Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children, Ann Intensive Care., 10, 69, 10.1186/s13613-020-00690-8

Licciardi, 2020, SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children, Pediatrics., 10.1542/peds.2020-1711

Toubiana, 2020, Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study, BMJ., 369, m2094, 10.1136/bmj.m2094

Whittaker, 2020, Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, JAMA., 10.1001/jama.2020.10369

Cheung, 2020, Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City, JAMA., 10.1001/jama.2020.10374

Chiotos, 2020, Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series, J Pediatric Infect Dis Soc., 10.1093/jpids/piaa069

Waltuch, 2020, Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department, Am J Emerg Med., 10.1016/j.ajem.2020.05.058

Ramcharan, 2020, Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital, Pediatr Cardiol., 10.1007/s00246-020-02391-2

2020

Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet., 395, 1417, 10.1016/S0140-6736(20)30937-5

Long, 2020, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med., 10.1038/s41591-020-0965-6

Choi, 1997, Clonal expansion of CD8+ T cells in Kawasaki disease, J Immunol., 159, 481, 10.4049/jimmunol.159.1.481

Brogan, 2008, T cell activation profiles in Kawasaki syndrome, Clin Exp Immunol., 151, 267, 10.1111/j.1365-2249.2007.03567.x

Shulman, 2015, Kawasaki disease: insights into pathogenesis and approaches to treatment, Nat Rev Rheumatol., 11, 475, 10.1038/nrrheum.2015.54

Rowley, 2000, IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease, J Infect Dis., 182, 1183, 10.1086/315832

Lukassen, 2020, SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells, EMBO J., 39, e105114, 10.15252/embj.20105114

Takahashi, 2014, Update on etio and immunopathogenesis of Kawasaki disease, Curr Opin Rheumatol., 26, 31, 10.1097/BOR.0000000000000010

Jia, 2010, The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease, Clin Exp Immunol., 162, 131, 10.1111/j.1365-2249.2010.04236.x

Wu, 2020, TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib, J Microbiol Immunol Infect., 53, 368, 10.1016/j.jmii.2020.03.005

Esper, 2005, Association between a novel human coronavirus and Kawasaki disease, J Infect Dis., 191, 499, 10.1086/428291

Toniati, 2020, Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy, Autoimmun Rev., 19, 102568, 10.1016/j.autrev.2020.102568

Nozawa, 2017, Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki's disease, N Engl J Med., 377, 1894, 10.1056/NEJMc1709609

Kobayashi, 2006, Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease, Circulation., 113, 2606, 10.1161/CIRCULATIONAHA.105.592865

Kobayashi, 2012, Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial, Lancet., 379, 1613, 10.1016/S0140-6736(11)61930-2

Miyata, 2018, Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study, Lancet Child Adolesc Health., 2, 855, 10.1016/S2352-4642(18)30293-1

Terai, 2002, Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease, Pediatr Infect Dis J., 21, 777, 10.1097/00006454-200208000-00015

Sun, 2020, The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?, Clin Chim Acta., 508, 122, 10.1016/j.cca.2020.05.027

Sun, 2020, Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience, J Autoimmun., 10.1016/j.jaut.2020.102473

Perico, 1996, Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation, J Am Soc Nephrol., 7, 594, 10.1681/ASN.V74594

Imazio, 2005, Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial, Circulation., 112, 2012, 10.1161/CIRCULATIONAHA.105.542738

Tardif, 2019, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med., 381, 2497, 10.1056/NEJMoa1912388

Kociol, 2020, Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association, Circulation., 141, e69, 10.1161/CIR.0000000000000745

Deftereos, 2020, Effect of Colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open., 3, e2013136, 10.1001/jamanetworkopen.2020.13136

Busse, 2020, COVID-19 and the RAAS-a potential role for angiotensin II?, Crit Care., 24, 136, 10.1186/s13054-020-02862-1

Zangrillo, 2020, Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series, Crit Care., 24, 227, 10.1186/s13054-020-02928-0